CMPX stock Statistics — Compass Therapeutics, Inc. filings, insiders & smart money

Price and daily changeSign in

Earnings4 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-07-28 · filed common shares: 180.08M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.23%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 22.65%
Short ratioDays to cover, as published by FINRA: 17.26
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 47.00%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 46.30%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin (nine months)Nine months: 2024-01-01 to 2024-09-30 · Not annualized: -4711.88%
Net margin: —
EBITDA margin (nine months)Nine months: 2024-01-01 to 2024-09-30 · Not annualized: -4659.06%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -56.66%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -47.87%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPS

—

EPS (fwd)

Cash & equivalentsas of Jun 26: $35.45M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $9.63M
Debt / equityas of Jun 26: 5.80%
Current ratioas of Jun 26: 11.22
Quick ratio: —
Operating cash flowTTM to Jun 26: -$56.11M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$56.37M
TTM revenue / diluted share: —